AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly ...

D. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of ...

In this article, we are going to take a look at where AVITA Medical Inc. (NASDAQ:RCEL) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty ...

Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat ...

Avita Medical said the U.S. Food and Drug Administration has approved the company's premarket approval supplement for Recell Go mini, a system to treat smaller wounds. The Recell Go mini is a line ...